Pulmonary Fibrosis Clinical Trials 2023
Browse 61 Pulmonary Fibrosis Medical Studies Across 159 Cities
8 Phase 3 Trial · 550 Pulmonary Fibrosis Clinics
All Participantsfor Pulmonary Fibrosis
EV-Pure™ And WJ-Pure™ Plus Standard Carefor Pulmonary Fibrosis
68Ga-FAPi-46for Interstitial Lung Disease
68Ga-FAP-2286for Pulmonary Fibrosis
Non-pharmacological Cough Control Therapyfor Pulmonary Fibrosis
Nintedanibfor Pulmonary Fibrosis
BIO 300 Oral Suspensionfor COVID-19
Nasal Delivery Of High-Flow Air And Oxygen Therapyfor Shortness of Breath
[68Ga]CBP8for Lung Cancer
Healthy Participantsfor Chronic Obstructive Pulmonary Disease
What Are Pulmonary Fibrosis Clinical Trials?
Pulmonary Fibrosis is a group of over 200 lung diseases that cause the lung tissues to become damaged and scarred. The scarred lung tissues thicken over time, making normal breathing difficult for the patient.
Pulmonary Fibrosis clinical trials are conducted to better understand the condition, individual diseases, and potential treatments that are both safe and effective and don’t negatively interact with other treatments or trigger other conditions.
Why Is Pulmonary Fibrosis Being Studied Through Clinical Trials?
Pulmonary Fibrosis clinical trials help researchers and medical professionals understand the disease and its treatment better. These trials are also conducted to determine which treatments are effective for which types of Pulmonary Fibrosis and which drugs may have potential side effects. These trials are conducted on Pulmonary Fibrosis patients and cover an extensive range of treatments/drugs, from Chinese herbal medicine to novel drugs.
Pulmonary Fibrosis clinical trials also cover topics like early detection, diagnostic processes, and its interaction with events like pregnancies.
What Are The Types of Treatments Available For Pulmonary Fibrosis?
The treatments offered to Pulmonary Fibrosis patients vary based on the severity of the disease and the tolerance potential of the patient. There are four common treatments for Pulmonary Fibrosis.
For many patients, Pulmonary rehabilitation can lead to some significant improvements. The idea behind this type of treatment is to prepare the body to better handle the adverse symptoms associated with the disease.
There are multiple drugs/medications that have shown promising results in reducing the scarring of the lungs and slowing down the symptoms associated with thickening lung muscles. Two drugs are approved by the FDA for the treatment and are generally considered safe.
A lot of patients need oxygen therapy to better manage their condition. It doesn’t _treat _the condition itself, but it offers relief to the patient and ensures that an adequate amount of oxygen is reaching the body.
A lung transplant, if the recipient's body properly accepts the new lungs, can offer complete relief to Pulmonary Fibrosis patients. But the procedure itself is complicated, and the risks are relatively higher compared to other treatments.
What Are Some Recent Breakthrough Clinical Trials For Pulmonary Fibrosis?
2019: Long-term Treatment Of Pulmonary Fibrosis with PRM-151 - PRM-151 is a recombinant human pentraxin 2 protein that has shown promising results in a clinical trial including 111 patients. Seventy-four were given the protein over a period of 28 weeks, and it was found to be quite well-tolerated.
2023: Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis - An inhibitor, BI 1015550, has been tested in a phase-2 clinical trial with a placebo control in place. One hundred forty-seven people were randomly selected and assigned the inhibitor or the placebo. The inhibitor showed promising results though there were consistent adverse effects for a small percentage of the sample group. It has been granted FDA breakthrough therapy status.
Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Pulmonary Fibrosis Clinical Trial Research?
Pulmonary Fibrosis Foundation - The foundation is dedicated to treatments and, ideally, a cure for Pulmonary Fibrosis. It has been involved in over 100 clinical trials on Pulmonary Fibrosis, representing more than 12% of all known clinical trials.